ANIPANI Pharmaceuticals, Inc.
Price
-24%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: the market
Quality strong, no red flags, undemanding price, growth steady, the market against it.
ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ").
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $266M in Q2 2026 (quarter ended Jun 30, 2026), up 26% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $25M (9.3% of revenue). For the full year FY2025, revenue was $883M (+44% year on year) and net income $78M. Its largest product in Q2 2026 was Total Sales Of Generics And Other at $101M, 39.4% of the disclosed total, just ahead of Sales Of Generic Pharmaceutical Products at 38.8%. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 24, 2026On August 19, 2026, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders.Director or officer change · Form 8-K
- Aug 7, 2026ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results.Earnings release · press release
- May 21, 2026ANI Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the stockholders of the Company approved the Company’s Amended and Restated 2022 Stock Incentive Plan (the “Amended 2022 Stock Plan”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $255.3MThe company’s own SEC segment disclosure.
- Total Sales Of Generics And Other$100.7M39%
- Sales Of Generic Pharmaceutical Products$99.1M39%
- Sales Of ILUVIEN And YUTIQ$18.7M7%
- Sales Of Established Brand Royalties And Other$17.7M7%
- Sales Of Established Brands$11.8M5%
- Unapproved Products$5.7M2%
- Other (1)$1.6M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #9 of 41 by RyuScore